True Care Biomedix

True Care Biomedix is an Indian pharmaceutical exporter specializing in the development, manufacturing, and global supply of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2008, the company operates as a 100% Export Oriented Unit (E.O.U.) under the jurisdiction of the Directorate General of Foreign Trade (DGFT), India. Its manufacturing facilities are located in Gujarat, India, with the business office situated at 201, "TORAN", Vikas Nagar, Old Padra Main Road, Vadodara 390020, and the manufacturing site at College Road, Balasinor, Mahisagar – 388255. The company is registered under the Corporate Identification Number (CIN) provided by the Ministry of Corporate Affairs, India. While specific revenue figures are not publicly disclosed, True Care Biomedix has demonstrated a consistent export performance, with a total export value of $1.7 million USD and 34 shipments across two therapeutic categories between 2022 and 2026. The company employs a dedicated team committed to delivering high-quality pharmaceutical products globally.

True Care Biomedix operates state-of-the-art manufacturing facilities in Gujarat, India, adhering to current Good Manufacturing Practice (cGMP) standards. The manufacturing site in Balasinor, Mahisagar, is equipped to produce a wide range of solid oral dosage forms, including tablets and capsules, with a monthly production capacity of 200 million tablets and 50 million capsules. These facilities are designed to maintain the highest quality standards, featuring temperature- and dust-controlled environments to ensure product integrity. The company emphasizes energy conservation and efficient production strategies, utilizing high-quality materials to maximize productivity. All processes and equipment undergo rigorous validation to assure consistent quality, aligning with international and national regulations.

Specific details regarding the CEO, CFO, and other key executives of True Care Biomedix are not publicly disclosed. However, the company's leadership is characterized by a team of experienced professionals dedicated to upholding the company's mission of delivering high-quality pharmaceutical products globally. The management team emphasizes a system-driven organization, fostering ample opportunities for team members to contribute to the company's growth and success.

True Care Biomedix's export activities are primarily focused on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Between 2022 and 2026, the company reported a total export value of $1.7 million USD across 34 shipments, with products spanning two therapeutic categories. The top five products exported include Docusate (57.2% of exports) and Diphenhydramine (42.8% of exports). The company's portfolio is entirely concentrated on these five products, indicating a strategic focus on specific therapeutic areas. While True Care Biomedix has demonstrated a consistent export performance, specific details regarding regulatory filings, approvals, and market access status in the US, EU, UK, Australia, and Japan are not publicly available. The company's adherence to cGMP standards and its status as a 100% Export Oriented Unit (E.O.U.) suggest a commitment to meeting international regulatory requirements.

True Care Biomedix's export data indicates a focus on specific therapeutic categories, with a significant portion of exports in the gastrointestinal and antihistamines & allergy segments. While the company's export activities are primarily directed towards these therapeutic areas, specific information regarding its penetration into emerging markets in Africa, Latin America, and Southeast Asia, as well as WHO prequalification status, is not publicly available. The company's adherence to cGMP standards and its status as a 100% Export Oriented Unit (E.O.U.) suggest a commitment to meeting international regulatory requirements, which may facilitate access to these emerging markets.

True Care Biomedix's export data reveals a concentrated portfolio, with the top five products accounting for 100% of exports. This indicates a strategic focus on specific therapeutic areas, particularly gastrointestinal and antihistamines & allergy segments. The company's adherence to cGMP standards and its status as a 100% Export Oriented Unit (E.O.U.) suggest a commitment to meeting international regulatory requirements, which may facilitate access to various global markets. However, specific details regarding the company's geographic diversification, concentration risk, and strategic direction are not publicly available.

Specific details regarding True Care Biomedix's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's adherence to cGMP standards and its status as a 100% Export Oriented Unit (E.O.U.) suggest a commitment to meeting international regulatory requirements, which may include compliance with FDA standards. However, without publicly accessible records, a comprehensive assessment of the company's FDA status cannot be conducted.

Specific information regarding True Care Biomedix's WHO prequalification, EU GMP certificates, and EDQM status is not publicly available. The company's adherence to cGMP standards and its status as a 100% Export Oriented Unit (E.O.U.) suggest a commitment to meeting international regulatory requirements, which may include compliance with WHO and EU GMP standards. However, without publicly accessible records, a comprehensive assessment of the company's certifications cannot be conducted.

Specific details regarding True Care Biomedix's CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly available. The company's adherence to cGMP standards and its status as a 100% Export Oriented Unit (E.O.U.) suggest a commitment to meeting national regulatory requirements. However, without publicly accessible records, a comprehensive assessment of the company's compliance with Indian regulatory authorities cannot be conducted.

As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to True Care Biomedix. The company's adherence to cGMP standards and its status as a 100% Export Oriented Unit (E.O.U.) suggest a commitment to maintaining compliance with international regulatory requirements. However, without publicly accessible records, a comprehensive assessment of the company's recent regulatory history cannot be conducted.

True Care Biomedix operates in the competitive landscape of finished pharmaceutical formulations, focusing on specific therapeutic areas such as gastrointestinal and antihistamines & allergy segments. While the company's export data indicates a concentrated portfolio, specific information regarding its top competitors in overlapping categories, market share comparisons, and head-to-head analyses is not publicly available. The company's adherence to cGMP standards and its status as a 100% Export Oriented Unit (E.O.U.) suggest a commitment to meeting international regulatory requirements, which may influence its competitive positioning.

True Care Biomedix's key differentiators include its adherence to current Good Manufacturing Practice (cGMP) standards, ensuring high-quality pharmaceutical products. The company's status as a 100% Export Oriented Unit (E.O.U.) under the Directorate General of Foreign Trade (DGFT) reflects its commitment to international trade and compliance with export regulations. Additionally, the company's manufacturing facilities in Gujarat, India, are designed to maintain the highest quality standards, featuring temperature- and dust-controlled environments to ensure product integrity.

True Care Biomedix's strategic direction focuses on the development, manufacturing, and global supply of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's adherence to cGMP standards and its status as a 100% Export Oriented Unit (E.O.U.) suggest a commitment to meeting international regulatory requirements. However, specific details regarding the company's focus on generics, specialty products, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services are not publicly available. Without publicly accessible records, a comprehensive assessment of the company's future outlook cannot be conducted.

Specific information regarding True Care Biomedix's overall track record, export volume and consistency, and reliability indicators is not publicly available. The company's adherence to cGMP standards and its status as a 100%